The subcutaneous injection can now be used with bortezomib, lenalidomide, and dexamethasone for newly diagnosed patients regardless of transplant eligibility.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/darzalex-faspro-quadruplet-okd-transplant-ineligible-2026a10002sh?src=rss
Author :
Publish date : 2026-01-29 04:57:00
Copyright for syndicated content belongs to the linked Source.